

Peter A Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1585459/publications.pdf>

Version: 2024-02-01

76
papers

34,192
citations

38660

50
h-index

79541

73
g-index

77
all docs

77
docs citations

77
times ranked

36143
citing authors

#	ARTICLE	IF	CITATIONS
1	The fundamental role of epigenetic events in cancer. <i>Nature Reviews Genetics</i> , 2002, 3, 415-428.	7.7	4,872
2	Functions of DNA methylation: islands, start sites, gene bodies and beyond. <i>Nature Reviews Genetics</i> , 2012, 13, 484-492.	7.7	4,840
3	The Epigenomics of Cancer. <i>Cell</i> , 2007, 128, 683-692.	13.5	4,039
4	Epigenetics in human disease and prospects for epigenetic therapy. <i>Nature</i> , 2004, 429, 457-463.	13.7	2,833
5	Cancer-epigenetics comes of age. <i>Nature Genetics</i> , 1999, 21, 163-167.	9.4	2,125
6	Cellular differentiation, cytidine analogs and DNA methylation. <i>Cell</i> , 1980, 20, 85-93.	13.5	1,756
7	Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. <i>Cancer Cell</i> , 2006, 9, 435-443.	7.7	1,253
8	DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts. <i>Cell</i> , 2015, 162, 961-973.	13.5	1,075
9	Cancer Genetics and Epigenetics: Two Sides of the Same Coin?. <i>Cancer Cell</i> , 2012, 22, 9-20.	7.7	966
10	Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer. <i>Cancer Cell</i> , 2014, 26, 577-590.	7.7	959
11	Targeting the cancer epigenome for therapy. <i>Nature Reviews Genetics</i> , 2016, 17, 630-641.	7.7	888
12	Rethinking how DNA methylation patterns are maintained. <i>Nature Reviews Genetics</i> , 2009, 10, 805-811.	7.7	693
13	Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. <i>Blood</i> , 2002, 100, 2957-2964.	0.6	511
14	Cooperativity between DNA Methyltransferases in the Maintenance Methylation of Repetitive Elements. <i>Molecular and Cellular Biology</i> , 2002, 22, 480-491.	1.1	508
15	5-Methylcytosine, Gene Regulation, and Cancer. <i>Advances in Cancer Research</i> , 1983, 40, 1-30.	1.9	396
16	Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules. <i>Genome Research</i> , 2012, 22, 2497-2506.	2.4	381
17	Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. <i>Oncotarget</i> , 2014, 5, 587-598.	0.8	367
18	Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). <i>Nucleic Acids Research</i> , 1997, 25, 2529-2531.	6.5	351

#	ARTICLE	IF	CITATIONS
19	Epigenetic therapy in immune-oncology. <i>Nature Reviews Cancer</i> , 2019, 19, 151-161.	12.8	345
20	Alterations of immune response of non-small cell lung cancer with Azacytidine. <i>Oncotarget</i> , 2013, 4, 2067-2079.	0.8	336
21	Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 12979-12984.	3.3	325
22	Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. <i>Nature</i> , 1977, 267, 364-366.	13.7	322
23	p53 and treatment of bladder cancer. <i>Nature</i> , 1997, 385, 123-124.	13.7	266
24	DNA Methylation Screening Identifies Driver Epigenetic Events of Cancer Cell Survival. <i>Cancer Cell</i> , 2012, 21, 655-667.	7.7	240
25	Delivery of 5-Aza-2-Deoxycytidine to Cells Using Oligodeoxynucleotides. <i>Cancer Research</i> , 2007, 67, 6400-6408.	0.4	204
26	Role of Nucleosomal Occupancy in the Epigenetic Silencing of the MLH1 CpG Island. <i>Cancer Cell</i> , 2007, 12, 432-444.	7.7	189
27	Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 14080-14085.	3.3	186
28	Selective Anchoring of DNA Methyltransferases 3A and 3B to Nucleosomes Containing Methylated DNA. <i>Molecular and Cellular Biology</i> , 2009, 29, 5366-5376.	1.1	179
29	Vitamin C increases viral mimicry induced by 5-aza-2-deoxycytidine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10238-10244.	3.3	171
30	Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation. <i>Molecular Cancer Research</i> , 2004, 2, 62-72.	1.5	151
31	Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. <i>Developmental Biology</i> , 1978, 66, 57-71.	0.9	147
32	DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins in somatic cells. <i>Nature Communications</i> , 2016, 7, 11453.	5.8	109
33	DNA methylation enables transposable element-driven genome expansion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 19359-19366.	3.3	109
34	Bivalent Regions of Cytosine Methylation and H3K27 Acetylation Suggest an Active Role for DNA Methylation at Enhancers. <i>Molecular Cell</i> , 2016, 62, 422-431.	4.5	106
35	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacytidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , 2017, 23, 2691-2701.	3.2	106
36	Nucleosomes Containing Methylated DNA Stabilize DNA Methyltransferases 3A/3B and Ensure Faithful Epigenetic Inheritance. <i>PLoS Genetics</i> , 2011, 7, e1001286.	1.5	103

#	ARTICLE	IF	CITATIONS
37	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1002-1017.	5.7	99
38	Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. <i>Blood</i> , 2012, 119, 206-216.	0.6	97
39	The role of DNA methylation in directing the functional organization of the cancer epigenome. <i>Genome Research</i> , 2015, 25, 467-477.	2.4	90
40	The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. <i>Human Molecular Genetics</i> , 2001, 10, 903-910.	1.4	87
41	Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells. <i>Cancer Research</i> , 2018, 78, 5754-5766.	0.4	83
42	Switching roles for DNA and histone methylation depend on evolutionary ages of human endogenous retroviruses. <i>Genome Research</i> , 2018, 28, 1147-1157.	2.4	82
43	Allele-specific methylation of the human c-Ha-ras-1 gene. <i>Cell</i> , 1987, 50, 711-717.	13.5	81
44	Overview of Cancer Epigenetics. <i>Seminars in Hematology</i> , 2005, 42, S3-S8.	1.8	79
45	DNA methylation as a target for drug design. <i>Pharmaceutical Research</i> , 1998, 15, 175-187.	1.7	71
46	PAX6 methylation and ectopic expression in human tumor cells. <i>International Journal of Cancer</i> , 2000, 87, 179-185.	2.3	69
47	Origins of Bidirectional Promoters: Computational Analyses of Intergenic Distance in the Human Genome. <i>Molecular Biology and Evolution</i> , 2003, 21, 463-467.	3.5	67
48	The Rate of CpG Mutation in Alu Repetitive Elements within the p53 Tumor Suppressor Gene in the Primate Germline. <i>Journal of Molecular Biology</i> , 1996, 258, 240-250.	2.0	66
49	Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study. <i>Oncotarget</i> , 2017, 8, 35326-35338.	0.8	66
50	Structure of nucleosome-bound DNA methyltransferases DNMT3A and DNMT3B. <i>Nature</i> , 2020, 586, 151-155.	13.7	61
51	Analysis of cyclin-dependent kinase inhibitor expression and methylation patterns in human prostate cancers. , 2000, 43, 233-242.		57
52	A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. <i>Clinical Cancer Research</i> , 2018, 24, 6160-6167.	3.2	46
53	Mutagenicity of nitric oxide is not caused by deamination of cytosine or 5-methylcytosine in double-stranded DNA. <i>Carcinogenesis</i> , 1994, 15, 2899-2903.	1.3	44
54	A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium. <i>Blood</i> , 2018, 131, 1145-1148.	0.6	44

#	ARTICLE	IF	CITATIONS
55	Identifying aggressive prostate cancer foci using a DNA methylation classifier. <i>Genome Biology</i> , 2017, 18, 3.	3.8	43
56	Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells. <i>Cancer Letters</i> , 2017, 401, 11-19.	3.2	42
57	Methylation inhibitors can increase the rate of cytosine deamination by (cytosine-5)-DNA methyltransferase. <i>Nucleic Acids Research</i> , 1996, 24, 3267-3275.	6.5	41
58	DNA methylation dynamics and dysregulation delineated by high-throughput profiling in the mouse. <i>Cell Genomics</i> , 2022, 2, 100144.	3.0	37
59	Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer. <i>Oncogene</i> , 1998, 17, 3021-3027.	2.6	34
60	Analysis of individual remodeled nucleosomes reveals decreased histone-DNA contacts created by hSWI/SNF. <i>Nucleic Acids Research</i> , 2009, 37, 5279-5294.	6.5	34
61	Mother-child transmission of epigenetic information by tunable polymorphic imprinting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E11970-E11977.	3.3	33
62	Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine. <i>Cancer Research</i> , 2020, 80, 2441-2450.	0.4	33
63	Nucleosome Positioning and NDR Structure at RNA Polymerase III Promoters. <i>Scientific Reports</i> , 2017, 7, 41947.	1.6	29
64	Identification of DNA Methylation-Independent Epigenetic Events Underlying Clear Cell Renal Cell Carcinoma. <i>Cancer Research</i> , 2016, 76, 1954-1964.	0.4	28
65	Endothelial Cells Degrade Extracellular Matrix Proteins Produced In Vitro. <i>Thrombosis and Haemostasis</i> , 1985, 54, 498-502.	1.8	28
66	Characterisation of human cells transformed in vitro by urethane. <i>Nature</i> , 1975, 256, 322-324.	13.7	26
67	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. <i>Nature Cancer</i> , 2021, 2, 1002-1017.	5.7	23
68	Nucleosome Occupancy and Methylome Sequencing (NOMe-seq). <i>Methods in Molecular Biology</i> , 2018, 1708, 267-284.	0.4	20
69	Oocyte age and preconceptual alcohol use are highly correlated with epigenetic imprinting of a noncoding RNA (<i>nc886</i>). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	18
70	Bladder cancer genotype stability during clinical progression. <i>Genes Chromosomes and Cancer</i> , 2000, 29, 26-32.	1.5	12
71	Enhancer-Dependent, Locus-Wide Regulation of the Imprinted Mouse Insulin-Like Growth Factor II Gene. <i>Journal of Biochemistry</i> , 1998, 123, 984-991.	0.9	5
72	Mesodermal determination genes: Evidence from DNA methylation studies. <i>BioEssays</i> , 1988, 8, 100-103.	1.2	4

#	ARTICLE	IF	CITATIONS
73	The cancer epigenome. <i>Genome</i> , 2013, 56, 540-541.	0.9	3
74	Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1. <i>Communications Biology</i> , 2022, 5, .	2.0	2
75	PAX6 methylation and ectopic expression in human tumor cells. , 2000, 87, 179.		1
76	Decoding the Chromatin Code. <i>Blood</i> , 2012, 120, SCI-4-SCI-4.	0.6	0